Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Calcium Supplements on Imatinib Mesylate (Gleevec) Pharmacokinetics in Healthy Volunteers (CSTI571BUS 280) (UPCI 08-072).

Next Previous
Search
Trial Profile

Effect of Calcium Supplements on Imatinib Mesylate (Gleevec) Pharmacokinetics in Healthy Volunteers (CSTI571BUS 280) (UPCI 08-072).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calcium carbonate (Primary) ; Imatinib (Primary)
  • Indications Cancer; Gastrointestinal disorders
  • Focus Pharmacokinetics

Most Recent Events

  • 13 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 28 Apr 2011 Planned end date changed from 1 May 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
  • 17 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top